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VIRAL HEPATITIS
Paracrine Signals From Liver Sinusoidal Endothelium
Regulate Hepatitis C Virus Replication
Ian A. Rowe,1,2 Sukhdeep K. Galsinh,1 Garrick K. Wilson,1 Richard Parker,2 Sarah Durant,3 Catalin Lazar,4
Norica Branza-Nichita,4 Roy Bicknell,3 David H. Adams,2 Peter Balfe,1 and Jane A. McKeating1,2
Hepatitis C virus (HCV) is a major cause of global morbidity, causing chronic liver
injury that can progress to cirrhosis and hepatocellular carcinoma. The liver is a large
and complex organ containing multiple cell types, including hepatocytes, sinusoidal en-
dothelial cells (LSEC), Kupffer cells, and biliary epithelial cells. Hepatocytes are the
major reservoir supporting HCV replication; however, the role of nonparenchymal cells
in the viral lifecycle remains largely unexplored. LSEC secrete factors that promote
HCV infection and transcript analysis identified bone morphogenetic protein 4 (BMP4)
as a candidate endothelial-expressed proviral molecule. Recombinant BMP4 increased
HCV replication and neutralization of BMP4 abrogated the proviral activity of LSEC-
conditioned media. Importantly, BMP4 expression was negatively regulated by vascular
endothelial growth factor A (VEGF-A) by way of a VEGF receptor-2 (VEGFR-2) primed
activation of p38 MAPK. Consistent with our in vitro observations, we demonstrate
that in normal liver VEGFR-2 is activated and BMP4 expression is suppressed. In con-
trast, in chronic liver disease including HCV infection where there is marked endothelial
cell proliferation, we observed reduced endothelial cell VEGFR-2 activation and a
concomitant increase in BMP4 expression. Conclusion: These studies identify a role for
LSEC and BMP4 in HCV infection and highlight BMP4 as a new therapeutic target for
treating individuals with liver disease. (HEPATOLOGY 2014;59:375-384)
See Editorial on Page 363
H
epatitis C virus (HCV) is a major cause of
global morbidity and mortality, with an esti-
mated 170 million infected individuals
worldwide. HCV causes chronic liver injury that can
progress to cirrhosis and is one of the leading causes
of hepatocellular carcinoma (HCC).1,2 Multiple drugs
targeting HCV replicase enzymes are currently in de-
velopment and the outlook for many is favorable;
however, combination therapies involving agents that
target host cell pathways may limit the development of
viral resistance and maximize treatment responses.
Hence, there is a need to define host cell pathways
used by HCV to aid the discovery of new targets for
future intervention strategies.
The liver is a large and complex organ containing
multiple cell types, including sinusoidal endothelial
cells (LSEC), stellate cells, Kupffer cells, and biliary
epithelial cells as well as hepatocytes. Hepatocytes are
the major reservoir supporting HCV replication and
the contribution of other cell types in the viral lifecycle
remain largely unexplored.3 LSEC hepatocyte interac-
tions are critical for normal liver development and
function and regulate the organ’s response to injury.4
One of the best-characterized paracrine signals between
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375
these endothelial and epithelial cells is vascular endo-
thelial growth factor-A (VEGF-A), which maintains
the sinusoidal endothelial fenestrated phenotype and
promotes hepatocyte growth factor expression in
response to injury.4-6
VEGF-A is a multifunctional cytokine originally
described for its ability to increase endothelial perme-
ability, and subsequently reported to have critical roles
in vascular development and cancer angiogenesis.7 We
previously reported that HCV infection promotes
VEGF-A expression, resulting in hepatocyte depolari-
zation and enhanced viral entry.8-10 Treating HCV-
infected hepatocytes with VEGF-A inhibitors, includ-
ing sorafenib, restored their ability to polarize and lim-
ited viral infection,8,11 suggesting a therapeutic role for
VEGF-A inhibitors in HCV infection.
These reports led us to investigate the role of LSEC
in the HCV lifecycle and to establish coculture systems
to study endothelial-epithelial cell interactions. We dis-
covered a new paracrine network that regulates HCV
replication. LSEC express bone morphogenetic protein
4 (BMP4) that increases hepatocyte permissivity to
support HCV replication. BMP4 is negatively regu-
lated at the transcriptional level by VEGF-A activation
of VEGF receptor-2 (VEGFR-2) and downstream p38
MAPK signaling. Ex vivo studies demonstrate
increased BMP4 expression and reduced endothelial
cell VEGFR-2 activation in the diseased liver, high-
lighting new aspects of LSEC-hepatocyte crosstalk that
may limit the efficacy of anti-VEGF therapies in HCV
infection and suggesting therapeutic manipulation of
BMP4.
Materials and Methods
Clinical Material. Tissue for cell isolation or ex
vivo analysis was obtained from patients undergoing
liver transplantation for endstage liver disease, or from
donor liver surplus to surgical requirements at the
Queen Elizabeth Hospital, UK. Informed consent and
regional Ethics Committee approvals were given.
Cell Culture. LSEC were isolated from donor liver
tissue by enzymatic digestion, density centrifugation,
and immunomagnetic separation.12 Purity was greater
than 95% as judged by expression of the LSEC spe-
cific lectin L-SIGN. Cells were routinely cultured in
human endothelial basal media (Invitrogen) supple-
mented with 10% human serum, VEGF-A, and hepa-
tocyte growth factor (HGF) (both 10 ng/mL,
Peprotech) on tissue culture plastic coated with rat tail
collagen (Sigma), unless otherwise stated. Huh-7.5
cells (provided by Charles Rice, Rockefeller University)
were propagated in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS)/1% nonessential amino acids. Primary human
hepatocytes were isolated using previously published
protocols and maintained in Williams E medium
supplemented with 10% FBS / 5 mM HEPES/insulin/
dexamethasone. All cells were maintained at 37C in
5% CO2. Cocultures were established by seeding cells
at 4 3 104/cm2 at a 1:1 ratio in human endothelial ba-
sal media supplemented with 10% human serum.
Growth Factor and Pharmacologic Treat-
ments. LSEC or Huh-7.5 cells were seeded at 4 3
104/cm2 and allowed to adhere overnight in the ab-
sence of VEGF-A and HGF. The following day cells
were incubated with growth factors: VEGF-A, placen-
tal growth factor (PlGF), bone morphogenetic protein-
4 (BMP4) (all Peprotech), and VEGF-E (RELIATech)
at 10 ng/mL unless otherwise stated. Following stimula-
tion with growth factors or conditioned media, cells
were treated with neutralizing antibodies targeting
VEGF-A or BMP4 (R&D Systems) (10 lg/mL) as
indicated. VEGF receptor (VEGFR) 21 (18F1) and
VEGFR-2 (1121-B) neutralizing antibodies (ImClone
Systems) were used as described.13,14 LSEC were treated
with kinase inhibitors for 1 hour, the inhibitor
removed, and cells stimulated with VEGF-A as indi-
cated. Specifically these inhibitors target MEK1
(PD98059), p38 MAPK (SB203580), phospholipase C
(PLC, U73122), and PI3 kinase (wortmannin). For the
collection of conditioned media, cells were treated for
24 hours before harvest and stored at 220C. Mock
media was human endothelial basal media supple-
mented with 10% human serum that was incubated at
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37C for 24 hours. Conditioned media were diluted
1:2 with fresh media prior to use.
Quantitative Reverse-Transcription Polymerase
Chain Reaction (RT-PCR). Purified RNA samples
were amplified for target genes as indicated with com-
mercial quantification kits (ABI), or HCV RNA
(Primer Design) in a single tube RT-PCR in accordance
with the manufacturer’s instructions (Cells Direct kit,
Invitrogen). Fluorescence was monitored in an MxPro-
3000 PCR machine (Stratagene). Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was included as an
endogenous control for amplification efficiency and
RNA quantification.
HCV Genesis and Infection. JFH-1 was generated
as described.15 Briefly, RNA was transcribed in vitro
from full-length genomes using the RiboExpress T7
kit (Promega) and electroporated into Huh-7.5 cells.
Then 72 and 96 hours after electroporation superna-
tants were collected and stored immediately at 280C.
Virus-containing media were incubated with target
cells at a multiplicity of infection (MOI) of 0.01.
Infected cells were detected by methanol fixation and
staining for viral NS5A with monoclonal antibody
9E10 (provided by Charles Rice, Rockefeller Univer-
sity) and Alexa-488 antimouse IgG. Infection was
quantified by enumerating NS5A1 foci and infectivity
defined as the number of focus-forming units/mL.
Microarray Gene Expression Profile. An Agilent
44k genome microarray was used to analyze gene
expression. LSEC and HUVEC, each from two inde-
pendent donors, were seeded and treated with VEGF-
A (10 ng/mL) for 18 hours. RNA was extracted using
RNeasy Mini Kit (Qiagen) and labeled according to
the manufacturer’s instructions. RNA was hybridized
to the array in accordance with the manufacturer’s rec-
ommendations (Two-color Quick Amp labeling v. 5.7,
Agilent). Transcripts regulated >2-fold and with a
false-discovery rate of <10% were selected and ana-
lyzed using DAVID bioinformatics resources.16 Micro-
array data were uploaded to NCBI GEO (GSE41110
www.ncbi.nlm.nih.gov/geo).
Immunohistochemistry. Formalin-fixed paraffin-
embedded samples were obtained from liver tissue.
Immunohistochemistry was performed as reported.17
Immunoblotting. LSEC were harvested in CellLytic
MT buffer (Sigma) containing protease and phosphatase
inhibitors (Roche). Tissue samples were homogenized
(GentleMACS, Miltenyi) in CellLytic MT buffer and
lysates cleared by centrifugation. Proteins were separated
by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE), transferred to polyvinylidene
membranes, probed with anti-VEGF, anti-BMP4
(R&D systems), anti-VEGFR-2, anti-Y1175 VEGFR-2,
anti-VE-cadherin, anti-phospho p38 (all Cell Signaling),
or anti-CD31 (Dako) as indicated and horseradish per-
oxidase (HRP)-conjugated secondary antibody. Proteins
were detected by enhanced chemiluminescence
(Geneflow).
Statistics. Results are presented as mean 61 SD.
The Mann-Whitney U test or the Kruskal-Wallis test
with Dunn’s correction as appropriate were used for
statistical analysis.
Results
LSEC Stimulate HCV Replication. To investigate
whether LSEC secrete factors that regulate HCV repli-
cation, Huh-7.5 hepatoma cells were incubated with
conditioned media (CM) from LSEC, propagated in
the absence of exogenous growth factor supplements,
prior to infecting with HCV strain JFH-1. CM sig-
nificantly increased HCV infection of both Huh-7.5
cells (Fig. 1A) and primary human hepatocytes (Fig.
1B) with no detectable effect on cell viability (Fig.
1C). Similar effects were observed with LSEC isolated
from multiple donors (Supporting Fig. 1) and with
human umbilical vein endothelial cells (data not
shown), demonstrating that this effect is not specific
to liver sinusoidal endothelial cells. CM increased the
levels of HCV RNA in subgenomic replicon-bearing
cells, suggesting that these factor(s) promote infection
at the level of genome replication (Fig. 1D). To deter-
mine whether LSEC were able to stimulate replication
of other hepatotropic viruses we tested LSEC CM in
hepatitis B virus culture systems and failed to observe
any modulation of replication (data not shown).
These observations suggest a role for LSEC-derived
soluble mediators in specifically regulating HCV
replication.
VEGF-A Limits LSEC Expression of Proviral
Mediators. In vivo LSEC are continually exposed to
hepatocyte-derived VEGF-A and this growth factor has
been proposed to protect the liver against viral infec-
tion.5 We therefore measured the effect of VEGF-A on
LSEC expression of proviral soluble factors. VEGF-A
decreased the proviral activity of CM in a dose-
dependent manner (Fig. 2A). In contrast, treating
Huh-7.5 hepatoma cells with VEGF-A had no effect
on HCV infection (Fig. 2B). To further study these
paracrine signals, hepatoma cells were cocultured with
LSEC (Fig. 2C) and evaluated for their ability to sup-
port HCV infection in the presence or absence of a
neutralizing anti-VEGF-A antibody. We confirmed
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that LSEC do not support HCV infection (data not
shown) and neutralization of VEGF-A increased HCV
infectivity in the coculture system. These data are con-
sistent with a down-regulation of endothelial expressed
proviral factor(s) in the presence of VEGF-A signaling
in LSEC.
BMP4 Promotes HCV Replication and Is Sup-
pressed by VEGF. To identify LSEC-expressed provi-
ral factor(s) we used two complementary strategies.
First, molecular weight cutoff filters allowed us to
show that proviral activity in LSEC CM was >30 kDa
and <50 kDa in size (Supporting Fig. 2). Second,
messenger RNA (mRNA) microarray identified several
transcripts that were regulated by VEGF-A in both
LSEC and HUVEC. Differentially regulated tran-
scripts were validated by qRT-PCR (Supporting Fig. 3)
and those encoding a predicted soluble or secreted
product identified by DAVID analysis.16 Four genes
were identified that were negatively regulated by
VEGF-A in both endothelial cell types: CCL2, CXCL1,
BMP4, and CXCL2. Of these only BMP4 encodes a
protein with a molecular weight compatible with the
fractionation studies. LSEC were confirmed to express
BMP4 and expression was down-regulated by VEGF-A
(Fig. 3A,B). Furthermore, antibody neutralization of
BMP4 in LSEC CM ablated the proviral activity of the
CM (Fig. 3C). Importantly, treating Huh-7.5 cells or
primary human hepatocytes with recombinant BMP4
resulted in a dose-dependent increase in the number of
infected cells (Fig. 3D) and HCV RNA levels (Fig.
3E,F) with minimal effect on cellular proliferation. In
summary, these experiments demonstrate that LSEC
secrete BMP4 and this promotes hepatocellular permis-
sivity to support HCV replication.
VEGF-A Regulates BMP4 Expression in a VEGFR-
2 and p38 MAPK-Dependent Manner. VEGF iso-
forms that bind different receptors enabled us to study
the mechanism underlying VEGF-A regulation of
BMP4. VEGF-E selectively binds VEGFR-2 and sup-
presses BMP4 mRNA to similar levels as VEGF-A,
whereas PlGF that targets VEGFR-1 had no effect (Fig.
4A). To confirm a role for VEGFR-2 in LSEC modula-
tion of HCV replication, the endothelial cells were
treated with VEGF-A or VEGF-E and the CM
screened for its effect on HCV infection of Huh-7.5
cells. Consistent with the model that VEGFR-2 activa-
tion negatively regulates BMP4, VEGF-E or VEGF-A
ablated the proviral activity of the CM (Fig. 4B). These
data show that ligation of endothelial VEGFR-2 limits
BMP4 expression and hepatocellular HCV replication.
To identify VEGF-dependent signals that regulate
endothelial BMP4 expression we screened pharmaco-
logical inhibitors of known downstream pathways. Of
the inhibitors tested, only p38 MAPK inhibitor
SB20358018 ablated the effect of VEGF-A stimulation
on the proviral activity of LSEC CM (Fig. 5A).
VEGF-A activation of LSEC increases the level of
phosphorylated p38 MAPK in a VEGFR-2-dependent
manner (Fig. 5B), and SB203580 increased LSEC
BMP4 expression following VEGF-A treatment in a
dose-dependent manner (Fig. 5C). Finally, treating
LSEC with SB203580 prior to VEGF-A stimulation
restored HCV infectivity in a dose-dependent manner
(Fig. 5D). These experiments demonstrate that VEGF-
Fig. 1. LSEC secreted factors increase hepatocellular HCV replica-
tion. Conditioned media (CM) was collected from LSEC seeded at 4
3 104/cm2 for 24 hours in the absence of VEGF-A and was diluted
1:2 with fresh media and used to treat Huh-7.5 (A), or PHH (B) for
18 hours prior to infecting with HCV JFH-1. CM was replenished follow-
ing infection. HCV infection was enumerated by quantifying NS5A
expressing cells or HCV RNA levels as indicated and the data
expressed relative to mock-treated cells. In replicate experiments with
Huh-7.5, the number of cells following mock or CM treatment was
quantified after 48 hours (C). Huh-7.5 supporting a JFH-1 subgenomic
replicon were treated with CM for 48 hours and HCV RNA quantified
(D). Data are mean 61 SD of n5 4 donor LSEC CM. Statistical com-
parisons were made with the Mann-Whitney U test where *P< 0.05,
and **P< 0.01 versus mock CM.
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Fig. 2. Paracrine VEGF signaling
reduces HCV infection of LSEC-hepatocyte
co-cultures. CM was collected from LSEC-
treated with increasing concentrations of
recombinant VEGF-A and screened for its
effect on Huh-7.5 permissivity to support
HCV JFH-1 infection. Infection was enum-
erated by quantifying NS5A-expressing
cells and the data expressed relative to
mock control (black) (A). Data are mean
61 SD of n5 4 donor LSEC CM. Statisti-
cal comparisons were made with the
Kruskal-Wallis test with Dunn’s correction
where **P< 0.01 versus mock CM.
Recombinant VEGF-A (10 ng/mL) was
used to treat Huh-7.5 cells at the time of
HCV infection. Infectivity was assessed as
above and expressed relative to untreated
control (B). LSEC/Huh-7.5 cocultures were
established and a representative image is
shown where LSEC are labeled with
CMFDA cell tracker dye (C). LSEC/Huh-
7.5 cocultures were treated with neutraliz-
ing anti-VEGF antibody or irrelevant IgG
(10 lg/mL) prior to infecting with HCV
(C). Data are mean 61 SD of n5 4 do-
nor LSEC cocultures. Statistical compari-
sons with the Mann-Whitney U test where
**P< 0.01 versus IgG control.
Fig. 3. BMP4 is negatively regulated by VEGF and stimulates HCV replication. LSEC were starved of VEGF overnight and stimulated with VEGF-
A as indicated for 8 hours and lysed to quantify BMP4 mRNA (A) or protein (B). Conditioned media (CM) from untreated or VEGF-A treated
LSEC were incubated with a neutralizing anti-BMP4 antibody (10 lg/mL) and screened for its effect on Huh-7.5 permissivity (C). Huh-7.5 were
treated with recombinant BMP4 for 48 hours and the cells assessed for their proliferative capacity (D) and permissivity to support HCV JFH-1
infection. Infection was enumerated by quantifying NS5A-expressing cells (E) or HCV RNA (F). Primary hepatocytes were treated with BMP4 (100
ng/mL) for 18 hours, inoculated with HCV JFH-1, and infection assessed by measuring HCV RNA (G). Data are mean 61 SD of n5 4 donor
LSEC. Statistical comparisons were made with the Kruskal-Wallis test with Dunn’s correction (A,C,E,F), or the Mann-Whitney U test (G) and where
*P< 0.05, **P< 0.01, and ***P< 0.001 versus mock media or untreated control.
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A inhibits endothelial expression of BMP4 by way of
VEGFR-2 mediated p38 MAPK signaling.
Increased BMP4 Expression in the Inflamed Liv-
er. To determine the effect of liver disease on BMP4
expression we assessed mRNA and protein expression
in tissue from age-matched organ donors and patients
with HCV infection or alcohol-related liver disease
(ALD). We observed negligible BMP4 expression in
the normal liver, and a significant increase in both
mRNA and protein in the diseased samples (Fig.
6A,B). Attempts to stain BMP4 in liver tissue were
unsuccessful; however, qRT-PCR screening a variety of
cell types isolated from normal or diseased liver only
detected BMP4 mRNA in LSEC (Fig. 6C).
To confirm our in vitro observations that VEGF
regulates BMP4 expression in a VEGFR-2-dependent
manner, we measured VEGF-A, and basal and phos-
phorylated VEGFR-2 in liver tissue. Consistent with
previous reports we detected a predominantly sinusoi-
dal pattern of VEGFR-2 expression in human liver tis-
sue (Fig. 7A).6,19 We observed increased VEGF-A and
VEGFR-2 levels in diseased liver (Fig. 7A-C), consist-
ent with reports of angiogenesis associated with cirrho-
sis (reviewed20). Importantly, there was a substantial
increase in CD31-expressing endothelial cells in dis-
eased liver samples (Supporting Fig. 4). To assess
VEGFR-2 activation we quantified phosphorylated
protein by immunoblotting and observed variable re-
ceptor phosphorylation in normal and diseased tissue
(Fig. 7C,D) with no significant differences between
these conditions. Given the increased frequency of en-
dothelial cells noted in the diseased liver (Supporting
Fig. 4), we probed the western blots for endothelial
markers CD31 and VE-cadherin and noted increased
expression (Fig. 7C,D), allowing us to normalize phos-
phorylated VEGFR-2 levels to total endothelial cell
mass (Fig. 7E). These studies highlight an absolute
increase in endothelial cell numbers with minimal
change in the level(s) of activated VEGFR-2, suggest-
ing an overall reduction in VEGFR-2 phosphorylation
on a per-cell basis. This reduction in endothelial
VEGFR-2 activation associated with increased BMP4
expression and validates our in vitro observations.
VEGFR-1 has been reported to regulate VEGFR-2
activity21 and we confirmed that in vitro stimulation
of LSEC with VEGF-A induced VEGFR-1 expression
(Supporting Fig. 5A), suggesting that elevated
VEGFR-1 levels observed in the diseased liver may
explain the reduction in phosphorylated VEGFR-2.
Consistent with this model we observed a significant
increase in VEGFR1 mRNA levels by qRT-PCR in
both HCV and ALD tissue (Supporting Fig. 5B).
These ex vivo data support our in vitro findings that
endothelial VEGFR-2 activation limits BMP4 expres-
sion. In summary, this study highlights a new para-
crine pathway for VEGF-A to negatively regulate
sinusoidal endothelial expression of BMP4 that can
facilitate HCV replication (Fig. 8).
Discussion
We report that BMP4 promotes HCV replication in
hepatocytes and sinusoidal endothelial cells are the
major source of BMP4 in the diseased liver. We show
that BMP4 is negatively regulated by VEGF-A signal-
ing by way of a VEGFR-2-dependent pathway. We
Fig. 4. Endothelial BMP4 expression is regulated by way of VEGFR-
2. LSEC were starved of VEGF overnight and stimulated with VEGF-A,
PlGF, or VEGF-E (all 10 ng/mL) for 8 hours, lysed, and RNA prepared
for qRT-PCR analysis of BMP4 mRNA (A). Conditioned media (CM)
from LSEC treated with the above ligands was collected and used to
treat Huh-7.5 cells for 18 hours prior to infecting with HCV JFH-1 (B).
Data are mean 61 SD of n5 4 donor LSEC. Statistical comparisons
were made with the Kruskal-Wallis test with Dunn’s correction as
appropriate and where **P< 0.01, and ***P< 0.001, versus
untreated control, or mock media as indicated.
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observed increased VEGF-A expression in liver samples
from subjects with HCV-associated liver disease and
with ALD; however, this was associated with a reduc-
tion in per endothelial cell VEGFR-2 activation and
increased BMP4 expression, demonstrating the value
of studying both ligand and receptor phosphorylation
status. The increased levels of BMP4 observed in the
diseased liver may represent a physiological response to
injury, since BMP4 has been reported to play a role in
liver development22 and regeneration.23 We propose
that HCV has evolved to exploit the elevated levels of
BMP4 expression in the inflamed liver to promote vi-
ral replication.
BMP4 is a member of the transforming growth fac-
tor (TGF)-b superfamily. This family of growth fac-
tors bind type I and type II serine-threonine kinase
receptors and transduce intracellular signals through
both Smad and non-Smad-dependent pathways.24
There are conflicting reports on the effect of TGF-b
on HCV replication25,26; however, a recent small
interfering RNA (siRNA) screen to identify host path-
ways in the viral lifecycle reported that Smad5 knock-
down significantly reduced HCV replication.27 In
summary, these data provide general support for our
observations of a proviral effect of BMP4 on HCV
replication.
VEGF-A is the key regulator of endothelial cell phe-
notype and is critical for liver development and regen-
eration. Our studies suggest that VEGF-A activation
of the sinusoidal endothelium suppresses BMP4
expression in a healthy liver, maintaining an environ-
ment that is less favorable for HCV replication.
Fig. 5. p38 MAPK activation negatively regulates BMP4 expression. LSEC were pretreated with control solvent or kinase inhibitors (all 10 lM)
for 1 hour, washed, and incubated with VEGF-A (10 ng/mL) as indicated. Conditioned media (CM) was collected and used to treat Huh-7.5 cells
for 18 hours prior to infecting with HCV JFH-1 (A). LSEC were incubated with anti-VEGFR neutralizing antibodies for 1 hour prior to treating with
VEGF ligands for 10 minutes before lysing for immunoblotting (B). LSEC were incubated with increasing concentrations of SB203580, or solvent
control, before washing and treating with VEGF-A (10 ng/mL) for 8 hours. Cellular BMP4 levels were measured by qRT-PCR (C) or CM collected
and used to treat Huh-7.5 cells for 18 hours prior to infecting with HCV JFH-1 (D). Data are mean 61 SD of n5 4 donor LSEC. Statistical com-
parisons were made with the Kruskal-Wallis test with Dunn’s correction where *P< 0.05, **P< 0.01, and ***P< 0.001 versus mock media or
untreated control as indicated.
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LeCouter et al.5 reported that the major effects of
VEGF-A in protecting the liver from chemical injury
in a murine model were mediated by way of VEGFR-
1; in contrast, our studies demonstrate a role for endo-
thelial VEGFR-2-mediated p38 MAPK activation in
regulating BMP4 expression. HCV infection has been
reported to stimulate VEGF-A expression8-10 that may
explain the elevated levels of VEGFR-1 levels we and
others28 observed in the infected liver. The function(s)
of VEGFR-1 are complex and include acting as a
decoy molecule to trap VEGF-A and thereby limit
VEGFR-2 activation.21 Mahasreshti et al.29 reported
that increased levels of soluble VEGFR-1 drive liver
injury by modulating VEGFR-2 activity. Thus,
increased hepatic VEGFR-1 levels may limit VEGFR-
2 activation and promote BMP4 expression in the dis-
eased liver.
Our studies uncover a new paracrine network link-
ing endothelial and epithelial cells of the liver. We pre-
viously reported that VEGF-A reduced hepatocyte
permeability and promoted HCV entry in HepG2
cells,8 suggesting that anti-VEGF therapies may limit
HCV infection. While this observation appears to
contradict the findings presented here, we believe the
principal difference between published studies and the
current one is explained by the presence of endothelial
cells in the experimental systems. We demonstrate that
BMP4 stimulates HCV RNA replication and antago-
nizing VEGF-A in the LSEC-hepatoma coculture pro-
motes viral replication. In contrast, VEGF-A acts
directly on polarized hepatocytes to reduce their per-
meability and promotes virus particle entry. Hence,
the relative concentrations of VEGF-A and BMP4 in
the liver are likely to impact different steps of the
HCV lifecycle. Our observations caution against tar-
geting VEGF-A and highlight the need for models
that recapitulate the hepatic microenvironment to
screen host targeting adjunctive therapies. It is note-
worthy that the current chimeric mouse models that
support HCV infection do not recapitulate the normal
sinusoidal environment between human hepatocytes
and mouse LSEC30 and may provide limited observa-
tions on the complex biology of the human liver.
BMP4 is implicated in hepatic fibrosis and animal
studies demonstrate increased BMP4 expression in
activated hepatic stellate cells.31 In contrast, we
observed low levels of BMP4 mRNA in activated liver
myofibroblasts isolated from diseased liver samples. It
is interesting to note that LSEC have been reported to
maintain stellate cells in a resting phenotype by way of
VEGF stimulated expression of nitric oxide.32 Conse-
quently, factors that limit VEGF-A activity are likely
to promote fibrogenesis through reduced nitric oxide
synthesis and increased BMP4 expression. BMP4 has
also been implicated in the development of several
cancers including HCC,33,34 a major cause of mortal-
ity in HCV-infected patients. We detected increased
BMP4 and VEGF mRNA and protein in liver tissue
from patients with alcoholic cirrhosis, suggesting that
this pathway is associated with liver injury and may
promote HCC-associated pathology by activating he-
patocytes and endothelial cells.
In summary, we have discovered a novel interaction
between liver endothelial cells and hepatocytes, and in
particular a new paracrine network where hepatocellu-
lar VEGF-A suppresses endothelial BMP4 expression
by activating p38 MAPK by way of VEGFR-2. The
observation that BMP4 promotes HCV replication
suggests a new therapeutic target for treating chronic
hepatitis C. Furthermore, reports showing a role for
BMP4 in liver development and in the response to
injury suggests that targeting this pathway may have
profound effects on pathophysiologically relevant proc-
esses in liver disease and carcinogenesis.
Fig. 6. Elevated BMP4 in chronic liver disease. Liver biopsy protein
lysates (30 lg) (A) or RNA (B,C) from normal, HCV-infected or
alcohol-related liver disease (each n5 6) were immunoblotted for
BMP4 (A) and qRT-PCR used to quantify BMP4 expression (B). West-
ern blot depicts three representative samples and BMP4 expression is
shown relative to normal samples and represents the mean value of
all samples. Statistical comparison was made using the Kruskal-Wallis
test with Dunn’s correction where *P< 0.05, and ***P< 0.001 ver-
sus normal liver samples. BMP4 expression in isolated human liver
cell populations was measured by qRT-PCR and expressed relative to
LSEC (PHH, primary human hepatocytes; BEC, biliary epithelial cells;
aLMF, activated liver myofibroblasts; n5 3 for each cell type) (C).
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Fig. 8. LSEC paracrine signals regulate HCV replication. In the normal liver BMP4 expression is suppressed by way of VEGFR-2/p38 MAPK sig-
naling (A). However, in the HCV-infected or diseased liver, reduced endothelial VEGFR-2 activation permits BMP4 expression that stimulates he-
patocellular permissivity to support HCV replication (B).
Fig. 7. Reduced endothe-
lial VEGFR-2 signaling in
chronic liver disease. Repre-
sentative image of VEGFR-2
expression in normal human
liver showing a predominant
sinusoidal staining pattern (A).
VEGF-A expression in normal
and diseased liver samples
(n5 6) was quantified by
qRT-PCR (B). Liver biopsy pro-
tein lysates (30 lg) from nor-
mal, HCV-infected, or alcohol-
related liver disease (each
n5 6, representative blots
from three donors shown)
were probed for proteins of in-
terest as indicated (C). Densi-
tometry was used to quantify
VE-cadherin (D) and phospho-
rylated VEGFR-2 expression,
allowing us to determine their
relative expression in all sam-
ples (E). Statistical compari-
sons were made with the
Kruskal-Wallis test with Dunn’s
correction where *P< 0.05,
and ***P< 0.001 versus
normal liver samples.
HEPATOLOGY, Vol. 59, No. 2, 2014 ROWE ET AL. 383
Acknowledgment: We thank Michelle Farquhar,
Colin Howard, and Nicola Fletcher for reading the ar-
ticle, T. Wakita and C. Rice for virus constructs and
Huh-7.5 cells, respectively, and ImClone Systems for
VEGF receptor antibodies.
References
1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C
virus infection. Lancet Infect Dis 2005;5:558-567.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med
2011;365:1118-1127.
3. Protzer U, Maini MK, Knolle PA. Living in the liver: hepatic infec-
tions. Nat Rev Immunol 2012;12:201-213.
4. Ding BS, Nolan DJ, Butler JM, James D, Babazadeh AO, Rosenwaks
Z, et al. Inductive angiocrine signals from sinusoidal endothelium are
required for liver regeneration. Nature 2010;468:310-315.
5. LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP,
et al. Angiogenesis-independent endothelial protection of liver: role of
VEGFR-1. Science 2003;299:890-893.
6. Carpenter B, Lin Y, Stoll S, Raffai RL, McCuskey R, Wang R. VEGF
is crucial for the hepatic vascular development required for lipoprotein
uptake. Development 2005;132:3293-3303.
7. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications
of angiogenesis. Nature 2011;473:298-307.
8. Mee CJ, Farquhar MJ, Harris HJ, Hu K, Ramma W, Ahmed A, et al.
Hepatitis C virus infection reduces hepatocellular polarity in a vascular
endothelial growth factor-dependent manner. Gastroenterology
2010;138:1134-1142.
9. Hassan M, Selimovic D, Ghozlan H, Abdel-Kader O. Hepatitis C virus
core protein triggers hepatic angiogenesis by a mechanism including
multiple pathways. HEPATOLOGY 2009;49:1469-1482.
10. Ripoli M, D’Aprile A, Quarato G, Sarasin-Filipowicz M, Gouttenoire
J, Scrima R, et al. Hepatitis C virus-linked mitochondrial dysfunction
promotes hypoxia-inducible factor 1 alpha-mediated glycolytic adapta-
tion. J Virol 2010;84:647-660.
11. Himmelsbach K, Sauter D, Baumert T, Ludwig L, Blum H, Hildt E.
New aspects of an anti-tumor drug: sorafenib efficiently inhibits HCV
replication. Gut 2009;58:1644-1653.
12. Liaskou E, Karikoski M, Reynolds GM, Lalor PF, Weston CJ, Pullen
N, et al. Regulation of mucosal addressin cell adhesion molecule 1
expression in human and mice by vascular adhesion protein 1 amine
oxidase activity. HEPATOLOGY 2010;53:661-672.
13. Jimenez X, Lu D, Brennan L, Persaud K, Liu M, Miao H, et al. A
recombinant, fully human, bispecific antibody neutralizes the biological
activities mediated by both vascular endothelial growth factor receptors
2 and 3. Mol Cancer Ther 2005;4:427-434.
14. Wu Y, Hooper AT, Zhong Z, Witte L, Bohlen P, Rafii S, et al. The
vascular endothelial growth factor receptor (VEGFR-1) supports
growth and survival of human breast carcinoma. Int J Cancer
2006;119:1519-1529.
15. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu
CC, et al. Complete replication of hepatitis C virus in cell culture. Sci-
ence 2005;309:623-626.
16. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat
Protoc 2009;4:44-57.
17. Reynolds GM, Harris HJ, Jennings A, Hu K, Grove J, Lalor PF, et al.
Hepatitis C virus receptor expression in normal and diseased liver tis-
sue. HEPATOLOGY 2008;47:418-427.
18. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, et al.
The selectivity of protein kinase inhibitors: a further update. Biochem J
2007;408:297-315.
19. Cao S, Yaqoob U, Das A, Shergill U, Jagavelu K, Huebert RC, et al.
Neuropilin-1 promotes cirrhosis of the rodent and human liver by
enhancing PDGF/TGF-beta signaling in hepatic stellate cells. J Clin
Invest 2010;120:2379-2394.
20. Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angio-
genesis in liver disease. J Hepatol 2009;50:604-620.
21. Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands
VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev
Cancer 2008;8:942-956.
22. Rossi JM, Dunn NR, Hogan BL, Zaret KS. Distinct mesodermal sig-
nals, including BMPs from the septum transversum mesenchyme, are
required in combination for hepatogenesis from the endoderm. Genes
Dev 2001;15:1998-2009.
23. Do N, Zhao R, Ray K, Ho KJ, Dib M, Ren X, et al. BMP4 is a novel
paracrine inhibitor of liver regeneration. Am J Physiol Gastrointest
Liver Physiol 2012;303:1220-1227.
24. Miyazono K, Kamiya Y, Morikawa M. Bone morphogenetic protein
receptors and signal transduction. J Biochem 2010;147:35-51.
25. Lin W, Weinberg EM, Tai AW, Peng LF, Brockman MA, Kim KA,
et al. HIV increases HCV replication in a TGF-beta1-dependent man-
ner. Gastroenterology 2008;134:803-811.
26. Murata T, Ohshima T, Yamaji M, Hosaka M, Miyanari Y, Hijikata M,
et al. Suppression of hepatitis C virus replicon by TGF-beta. Virology
2005;331:407-417.
27. Li Q, Brass AL, Ng A, Hu Z, Xavier RJ, Liang TJ, et al. A genome-
wide genetic screen for host factors required for hepatitis C virus prop-
agation. Proc Natl Acad Sci U S A 2009;106:16410-16415.
28. Huang XX, McCaughan GW, Shackel NA, Gorrell MD. Up-regulation
of proproliferative genes and the ligand/receptor pair placental growth
factor and vascular endothelial growth factor receptor 1 in hepatitis C
cirrhosis. Liver Int 2007;27:960-968.
29. Mahasreshti PJ, Kataram M, Wang MH, Stockard CR, Grizzle
WE, Carey D, et al. Intravenous delivery of adenovirus-mediated
soluble FLT-1 results in liver toxicity. Clin Cancer Res
2003;9:2701-2710.
30. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A,
et al. Hepatitis C virus replication in mice with chimeric human livers.
Nat Med 2001;7:927-933.
31. Fan J, Shen H, Sun Y, Li P, Burczynski F, Namaka M, et al. Bone mor-
phogenetic protein 4 mediates bile duct ligation induced liver fibrosis
through activation of Smad1 and ERK1/2 in rat hepatic stellate cells.
J Cell Physiol 2006;207:499-505.
32. Deleve LD, Wang X, Guo Y. Sinusoidal endothelial cells prevent rat
stellate cell activation and promote reversion to quiescence. HEPATO-
LOGY 2008;48:920-930.
33. McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S, et al. Human
ovarian carcinoma-associated mesenchymal stem cells regulate cancer
stem cells and tumorigenesis via altered BMP production. J Clin Invest
2011;121:3206-3219.
34. Maegdefrau U, Amann T, Winklmeier A, Braig S, Schubert T, Weiss
TS, et al. Bone morphogenetic protein 4 is induced in hepatocellular
carcinoma by hypoxia and promotes tumour progression. J Pathol
2009;218:520-529.
384 ROWE ET AL. HEPATOLOGY, February 2014
